14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NMTC vs SOLV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Solventum Corporation (SOLV) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas SOLV carries 41.4/100 (SELL) at $84.50 (11.2x Forward P/E, 5.9% operating margin).
Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SOLV 41.4/100 SELL), SOLV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.9% vs. -63.4% operating margin) and revenue trajectory (-7.0% vs. +16.3% YoY).
Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile SOLV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Instruments & Supplies value chain with $14.6B market capitalization and 5.9% operating margin.
OpEx & R&D Reinvestment47.9% of Rev ($3.91B)
90D Engineering Disclosures0 Published
Investor FAQ NMTC vs SOLV Key Questions & Quantitative Answers
As of Nov 20, 2026, Solventum Corporation (SOLV) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas SOLV carries 41.4/100 (SELL) at $84.50 (11.2x Forward P/E, 5.9% operating margin). Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SOLV 41.4/100 SELL), SOLV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.9% vs. -63.4% operating margin) and revenue trajectory (-7.0% vs. +16.3% YoY). Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile SOLV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SOLV leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with SOLV at -7.0% YoY revenue growth and +3.9% YoY earnings growth on $8.16B TTM revenue (53.8% gross margin, 5.9% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), NMTC cumulative revenue shifted N/A while SOLV shifted +2.3%. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus 47.9% of Rev ($3.91B) (0 disclosures) for SOLV.
SOLV screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas SOLV trades at 11.2x Forward P/E, 96.4x Trailing P/E, 1.22x PEG, and 2.4x EV/Revenue (0.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus SOLV (3.2% ROE) capital efficiency.
In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, SOLV carries 54.9% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.51β · 36% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.